Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[123I]-ADAM
- Development stage
- Unknown
- Lead developer
- University of Pennsylvania
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[123I]-ADAM is a radiopharmaceutical small molecule used as a diagnostic imaging agent for Single Photon Emission Computed Tomography (SPECT). It specifically binds to the serotonin transporter (SERT), allowing for the visualization and quantification of SERT availability in various brain regions, including the midbrain, medial temporal lobe, and basal ganglia. Developed and utilized in research at the University of Pennsylvania, it serves as a molecular imaging tool to investigate serotonergic dysfunction in psychiatric conditions. In the context of major depressive disorder (MDD), it has been employed to monitor changes in transporter binding density before and after therapeutic interventions, such as cognitive behavioral therapy (CBT), to better understand the biological mechanisms of treatment response.
- Other names
- 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamineADAMADAM SPECT
02
Targets
SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on [123I]-ADAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [123I]-ADAM.